Eisai Clinical Trials

A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer’s Disease

E2020-C086-339

Study Overview

E2020
donepezil
NCT01404169
Sep 2011 - Jul 2014
Alzheimer's disease
To demonstrate that donepezil hydrochloride 10 mg/day has superior efficacy compared with placebo for changes from Baseline to Week 24 in cognitive function in Chinese participants with severe Alzheimer's disease.

  • Male and female patients (aged 50 to 90 years)

  • Completed

  • Phase 3

  • China

Results

CSR Synopsis

No download available

Lay Summary

No download available

Publication reference citation

Jia J, Wei C, Jia L, Tang Y, Liang J, Zhou A, et al. Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer’s Disease: A Randomized Controlled Trial. Journal of Alzheimer’s Disease. 2017;56:1495-504.

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR